Hypericin Alleviates Chronic Kidney Disease–induced Left Ventricular Hypertrophy by Regulation of FGF23-FGFR4 Signaling Pathway
- 1 June 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 83 (6) , 588-601
Abstract
Chronic kidney disease (CKD) is a significant global health threat that imposes a substantial burden on both individuals and societies. CKD frequently correlates with cardiovascular events, particularly left ventricular hypertrophy (LVH), which contributes to the high mortality rate associated with CKD. Fibroblast growth factor 23 (FGF23), a hormone primarily involved in regulating calcium and phosphorus metabolism, has been identified as a major risk factor for LVH in CKD patients. Elevated serum FGF23 levels are known to induce LVH and myocardial fibrosis by activating the fibroblast growth factor receptor 4 (FGFR4) signal pathway. Therefore, targeting FGFR4 and its downstream signaling pathways holds potential as a treatment strategy for cardiac dysfunction in CKD. In our current study, we have discovered that Hypericin, a key component derived from Hypericum perforatum, has the ability to alleviate CKD-related LVH by targeting the FGFR4/phospholipase C gamma 1 (PLCγ1) signaling pathway. Through in vitro experiments using rat cardiac myocyte H9c2 cells, we observed that Hypericin effectively inhibits FGF23-induced hypertrophy and fibrosis by suppressing the FGFR4/PLCγ1/calcineurin/nuclear factor of activated T-cell (NFAT3) signaling pathway. In addition, our in vivo studies using mice on a high-phosphate diet and rat models of 5/6 nephrectomy demonstrated that Hypericin has therapeutic effects against CKD-induced LVH by modulating the FGFR4/PLCγ1/calcineurin/NFAT3 signaling pathway. In conclusion, our research highlights the potential of Hypericin as a candidate for the treatment of CKD-induced cardiomyopathy. By suppressing the FGFR4/PLCγ1 signaling pathway, Hypericin shows promise in attenuating LVH and myocardial fibrosis associated with CKD.Keywords
Funding Information
- National Natural Science Foundation of China (82073705)
- National Natural Science Foundation of China (82273842)
- Natural Science Funding of Zhejiang Province (LR22H300002)
- Wenzhou major scientific and technological innovation project (ZY2021023)
- Qianjiang Talent Plan of Zhejiang (QJD1902016)
This publication has 32 references indexed in Scilit:
- Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2022
- The regulation of FGF23 under physiological and pathophysiological conditionsPflügers Archiv - European Journal of Physiology, 2022
- FGFR4: A promising therapeutic target for breast cancer and other solid tumorsPharmacology & Therapeutics, 2020
- Paracrine Factors in Uremic CardiomyopathyJACC: Basic To Translational Science, 2020
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017The Lancet, 2020
- Macrophage-Derived Exosomal Mir-155 Regulating Cardiomyocyte Pyroptosis and Hypertrophy in Uremic CardiomyopathyJACC: Basic To Translational Science, 2020
- Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney diseaseKidney International, 2016
- Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular HypertrophyCell Metabolism, 2015
- Interference of antihypertrophic molecules and signaling pathways with the Ca2+?calcineurin?NFAT cascade in cardiac myocytesCardiovascular Research, 2004
- Increased Regulatory Activity of the Calcineurin/NFAT Pathway in Human Heart FailureEuropean Journal of Heart Failure, 2004